Basilea Pharmaceutica

Emerging Markets And Drug Resistance Will Drive Global Expansion

AnalystConsensusTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

27 Aug 25

Updated

27 Aug 25

AnalystConsensusTarget's Fair Value

CHF 81.34

43.0% undervalued

27 Aug

CHF 46.35

0.3%

-2.4%

0.3%

-2.4%

Author's Valuation

CHF 81.3

43.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

CHF 81.3

43.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

11.87%

Biotech revenue growth rate

12.30%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

3.96%

Calculation

CHF 82.83m

Earnings '28

14.08x

PE Ratio '28

CHF 1.17b

Market Cap '28

CHF 1.17b

Market Cap '28

12.76m

No. shares '28

CHF 91.38

Share Price '28

CHF 91.38 Share Price '28

Discounted to 2025 @ 3.96% p.a.

CHF 81.33

Fair Value '25